Any patent practitioner knows that §101 challenges are filed as a matter of course in patent infringement cases involving software and business methods. On the other hand, challenges under §101 are rarely used in cases. In fact, of the 490 ANDA cases filed since the Supreme Court’s decision in Alice Corp. Pty. v. CLS Bank Int’l 134 S.Ct. 2347 (2014), only six appear to address §101 (Alice) challenges. By utilizing §101 motions less than 2 percent of the time, generics are not fully availing themselves of the Supreme Court’s decisions in Alice, Mayo, and Myriad. As an example, and without providing an exhaustive list, generic pharmaceutical companies should, at a minimum, consider filing §101 motions in cases involving method of treatment, pK profiles, or polymorph patents.
Section 101: Interpretation and Applications
35 U.S.C. §101 provides that a patent may be granted to “[w]hoever invents or discovers any new and useful process, machine, manufacture, or composition of matter, or any new and useful improvement thereof[.]”
This content has been archived. It is available through our partners, LexisNexis® and Bloomberg Law.
To view this content, please continue to their sites.
Not a Lexis Subscriber?
Subscribe Now
Not a Bloomberg Law Subscriber?
Subscribe Now
LexisNexis® and Bloomberg Law are third party online distributors of the broad collection of current and archived versions of ALM's legal news publications. LexisNexis® and Bloomberg Law customers are able to access and use ALM's content, including content from the National Law Journal, The American Lawyer, Legaltech News, The New York Law Journal, and Corporate Counsel, as well as other sources of legal information.
For questions call 1-877-256-2472 or contact us at [email protected]